Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of CancerReportar como inadecuado




Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Biomedicine and BiotechnologyVolume 2010 2010, Article ID 956304, 13 pages

Review Article

Institute of Immunology, Medical Faculty, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany

Center for Regenerative Therapies Dresden, Tatzberg 47-49, 01307 Dresden, Germany

Department of Neurosurgery, Section Experimental Neurosurgery-Tumor Immunology, University Hospital, Technical University of Dresden, Fetscherstraße 74, 01307 Dresden, Germany

Received 30 November 2009; Accepted 15 February 2010

Academic Editor: Zhengguo Xiao

Copyright © 2010 Marc Cartellieri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

and T lymphocytes are powerful components of adaptive immunity, which essentially contribute to the elimination of tumors. Due to their cytotoxic capacity, T cells emerged as attractive candidates for specific immunotherapy of cancer. A promising approach is the genetic modification of T cells with chimeric antigen receptors CARs. First generation CARs consist of a binding moiety specifically recognizing a tumor cell surface antigen and a lymphocyte activating signaling chain. The CAR-mediated recognition induces cytokine production and tumor-directed cytotoxicity of T cells. Second and third generation CARs include signal sequences from various costimulatory molecules resulting in enhanced T-cell persistence and sustained antitumor reaction. Clinical trials revealed that the adoptive transfer of T cells engineered with first generation CARs represents a feasible concept for the induction of clinical responses in some tumor patients. However, further improvement is required, which may be achieved by second or third generation CAR-engrafted T cells.





Autor: Marc Cartellieri, Michael Bachmann, Anja Feldmann, Claudia Bippes, Slava Stamova, Rebekka Wehner, Achim Temme, and Marc Sch

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados